In response to the urgent need for increased vaccine manufacturing capacity amidst the COVID-19 pandemic, we are proud to announce our latest project: the development of a new industrial production process for ARNm synthesis enzymes. Supported by the ERDF of the European Union and the Junta de Castilla y León, this initiative aims to address the critical shortage of vaccine supplies by enhancing the efficiency and scalability of production.
By leveraging cutting-edge technology and strategic partnerships, we are committed to driving innovation and contributing to a more competitive and resilient healthcare ecosystem. Join us as we embark on this crucial mission to empower global vaccination efforts and safeguard public health.
RESEARCH AND DEVELOPMENT OF NEW ENZYMES FOR SYNTHESIS OF mRNA VACCINES
Dossier no: FAR-010500-2022-1
Main objective of the project: development of a new robust, reproducible, industrialisable and optimised production process for recombinant enzymes involved in the synthesis of messenger RNA (mRNA).
Deadline for completion: From 01/06/2022 to 22/11/2024.
Project funded by the European Union – Nest Generation EU, the Ministry of Industry, Trade and Tourism and the Transformation and Resilience Recovery Plan.
Grant awarded: 331,927.00€.
INVESTIGACIÓN Y DESARROLLO DE NUEVAS ENZIMAS PARA LA SÍNTESIS DE VACUNAS DE ARNm
Nº expediente: FAR-010500-2022-1
Objetivo principal del proyecto: desarrollo de un nuevo proceso productivo robusto, reproducible, industrializable y optimizado de las enzimas recombinantes que participan en la síntesis del ARN mensajero (ARNm).
Plazo de realización: Desde el 01/06/2022 al 22/11/2024
Proyecto financiado por la Unión Europea – Nest Generation EU, el Ministerio de Industria, Comercio y Turismo y el Plan de Recuperación Transformación y Resiliencia.
Subvención concedida: 331.927,00€
About 53Biologics:
53Biologics is a CDMO with specialized in biologics production, from pDNA, mRNA and proteins. It is a leading biopharma company providing services from preclinical and clinical development to GMP manufacturing, supporting our clients in getting their biological products to market as quickly as possible.
For more information contact Patricia De La Madrid, Marketing & Business Development Manager at 53Biologics through this email: pdelamadrid@53biologics.com
